{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:12Z","timestamp":1792790472048,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["PID2021-125282OB-I00"],"award-info":[{"award-number":["PID2021-125282OB-I00"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41375-024-02419-z","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T20:47:18Z","timestamp":1727297238000},"page":"2722-2726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma"],"prefix":"10.1038","volume":"38","author":[{"given":"Laura","family":"Martinez-Verbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4124-9788","authenticated-orcid":false,"given":"Yoana","family":"Veselinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Llin\u00e0s-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5021-6916","authenticated-orcid":false,"given":"Carlos A.","family":"Garc\u00eda-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Noguera-Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel L.","family":"Pato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bueno-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Campillo-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorea","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Oliver-Caldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-5423","authenticated-orcid":false,"given":"Oriol","family":"Cardus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi V.","family":"Salsench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Garc\u00eda-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Valeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeta A.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-3371","authenticated-orcid":false,"given":"Naroa","family":"Barrena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-9510","authenticated-orcid":false,"given":"Norma C.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-8790","authenticated-orcid":false,"given":"Felipe","family":"Pr\u00f3sper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Agirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4084-6815","authenticated-orcid":false,"given":"Gerardo","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4490-6093","authenticated-orcid":false,"given":"Manel","family":"Esteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"2419_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21207571","volume":"21","author":"P Peixoto","year":"2020","unstructured":"Peixoto P, Cartron PF, Serandour AA, Hervouet E. From 1957 to nowadays: a brief history of epigenetics. Int J Mol Sci. 2020;21:1\u201318.","journal-title":"Int J Mol Sci"},{"key":"2419_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.it.2020.06.002","volume":"41","author":"L Villanueva","year":"2020","unstructured":"Villanueva L, \u00c1lvarez-Errico D, Esteller M. The contribution of epigenetics to cancer immunotherapy. Trends Immunol. 2020;41:676\u201391.","journal-title":"Trends Immunol"},{"key":"2419_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.blre.2015.11.003","volume":"30","author":"Y Xia","year":"2016","unstructured":"Xia Y, Medeiros LJ, Young KH. Immune checkpoint blockade: releasing the brake towards hematological malignancies. Blood Rev. 2016;30:189\u2013200.","journal-title":"Blood Rev"},{"key":"2419_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41423-018-0168-y","volume":"16","author":"P Ku\u010dan Brli\u0107","year":"2019","unstructured":"Ku\u010dan Brli\u0107 P, Lenac Rovi\u0161 T, Cinamon G, Tsukerman P, Mandelboim O, Jonji\u0107 S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol. 2019;16:51\u201363.","journal-title":"Cell Mol Immunol"},{"key":"2419_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2022.979569","volume":"12","author":"C Muylaert","year":"2022","unstructured":"Muylaert C, Van Hemelrijck LA, Maes A, De Veirman K, Menu E, Vanderkerken K, et al. Aberrant DNA methylation in multiple myeloma: a major obstacle or an opportunity? Front Oncol. 2022;12:1\u201324.","journal-title":"Front Oncol"},{"key":"2419_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.semcancer.2021.06.022","volume":"83","author":"DM Avella Patino","year":"2022","unstructured":"Avella Patino DM, Radhakrishnan V, Suvilesh KN, Manjunath Y, Li G, Kimchi ET, et al. Epigenetic regulation of cancer immune cells. Semin Cancer Biol. 2022;83:377\u201383.","journal-title":"Semin Cancer Biol"},{"key":"2419_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells12030365","volume":"12","author":"S Keshari","year":"2023","unstructured":"Keshari S, Barrodia P, Singh AK. Epigenetic perspective of immunotherapy for cancers. Cells. 2023;12:1\u201320.","journal-title":"Cells"},{"key":"2419_CR8","unstructured":"The Multiple Myeloma Research Foundation (MMRF). CoMMpass Project. https:\/\/gdc.cancer.gov\/about-gdc\/contributed-genomic-data-cancer-research\/foundation-medicine\/multiple-myeloma-research-foundation-mmrf. Accessed: September 2022."},{"key":"2419_CR9","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1158\/1078-0432.CCR-19-3673","volume":"26","author":"E Lozano","year":"2020","unstructured":"Lozano E, Mena MP, D\u00edaz T, Martin-Antonio B, Leon S, Rodr\u00edguez-Lobato LG, et al. Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma. Clin Cancer Res. 2020;26:4688\u201398.","journal-title":"Clin Cancer Res"},{"key":"2419_CR10","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s43018-020-00131-2","volume":"1","author":"M Duran-Ferrer","year":"2020","unstructured":"Duran-Ferrer M, Clot G, Nadeu F, Beekman R, Baumann T, Nordlund J, et al. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. Nat Cancer. 2020;1:1066\u201381.","journal-title":"Nat Cancer"},{"key":"2419_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2217\/epi.15.114","volume":"8","author":"S Moran","year":"2016","unstructured":"Moran S, Arribas C, Esteller M. Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics. 2016;8:389\u201399.","journal-title":"Epigenomics"},{"key":"2419_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","volume":"24","author":"A Oliver-Cald\u00e9s","year":"2023","unstructured":"Oliver-Cald\u00e9s A, Gonz\u00e1lez-Calle V, Caba\u00f1as V, Espa\u00f1ol-Rego M, Rodr\u00edguez-Otero P, Reguera J, et al. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol. 2023;24:913\u201324.","journal-title":"Lancet Oncol"},{"key":"2419_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jtct.2023.11.014","volume":"30","author":"AK Mishra","year":"2024","unstructured":"Mishra AK, Schmidt TM, Martell EB, Chen AS, Dogru RE, Hematti P, et al. PD1+TIGIT+2B4+KLRG1+ cells might underlie T cell dysfunction in patients treated with BCMA-directed chimeric antigen receptor T cell therapy. Transpl Cell Ther. 2024;30:191\u2013202.","journal-title":"Transpl Cell Ther"},{"key":"2419_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00537-w","volume":"11","author":"A Leivas","year":"2021","unstructured":"Leivas A, Valeri A, C\u00f3rdoba L, Garc\u00eda-Ortiz A, Ortiz A, S\u00e1nchez-Vega L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11:1\u201311.","journal-title":"Blood Cancer J"},{"key":"2419_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.953849","volume":"13","author":"A Valeri","year":"2022","unstructured":"Valeri A, Garc\u00eda-Ortiz A, Castellano E, C\u00f3rdoba L, Maroto-Mart\u00edn E, Encinas J, et al. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Immunol. 2022;13:1\u201328.","journal-title":"Front Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02419-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02419-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02419-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T11:03:47Z","timestamp":1732532627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02419-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2419"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02419-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be considered as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}